ES2095802A1 - Composicion farmaceutica estabilizada y solvente de estabilizacion. - Google Patents

Composicion farmaceutica estabilizada y solvente de estabilizacion.

Info

Publication number
ES2095802A1
ES2095802A1 ES09402047A ES9402047A ES2095802A1 ES 2095802 A1 ES2095802 A1 ES 2095802A1 ES 09402047 A ES09402047 A ES 09402047A ES 9402047 A ES9402047 A ES 9402047A ES 2095802 A1 ES2095802 A1 ES 2095802A1
Authority
ES
Spain
Prior art keywords
solvent
pharmaceutical composition
stabilized
ricino
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ES09402047A
Other languages
English (en)
Inventor
Shreerham Nara Agharkar
Uday S Gogate
Thomas Cavanak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22433231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2095802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ES2095802A1 publication Critical patent/ES2095802A1/es
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSICION FARMACEUTICA ESTABILIZADA Y SOLVENTE DE ESTABILIZACION. COMPOSICION FARMACEUTICA ESTABILIZADA QUE CONTIENE PACLITAXEL, TENIPOSIDO, CAMPTOTECINA U OTROS AGENTES ANTINEOPLASICOS SUSCEPTIBLES A LA DEGRADACION DURANTE EL ALMACENAMIENTO, QUE SE PRODUCE UTILIZANDO UN SISTEMA DE SOLVENTES QUE CONTIENE UN BAJO CONTENIDO DE ANION CARBOXILATO. EL SISTEMA DE SOLVENTES ES UNA MEZCLA DE ETANOL Y ACEITE DE RICINO POLIOXIETILADO. EL ACEITE DE RICINO POLIOXIETILADO ES TRATADO CON UN ACIDO O PUESTO EN CONTACTO CON ALUMINA PARA REDUCIR EL CONTENIDO DE ANION CARBOXILATO DEL SOLVENTE. EL BAJO CONTENIDO DE ANION CARBOXILATO DEL SOLVENTE PROPORCIONA UNA VIDA DE ALMACENAMIENTO PROLONGADA Y DISMINUYE LA CANTIDAD DE SUBPRODUCTOS DE DEGRADACION.
ES09402047A 1993-09-29 1994-09-29 Composicion farmaceutica estabilizada y solvente de estabilizacion. Withdrawn ES2095802A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12802693A 1993-09-29 1993-09-29

Publications (1)

Publication Number Publication Date
ES2095802A1 true ES2095802A1 (es) 1997-02-16

Family

ID=22433231

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94115180T Expired - Lifetime ES2098842T3 (es) 1993-09-29 1994-09-27 Composicion farmaceutica estabilizada y disolvente estabilizante.
ES09402047A Withdrawn ES2095802A1 (es) 1993-09-29 1994-09-29 Composicion farmaceutica estabilizada y solvente de estabilizacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94115180T Expired - Lifetime ES2098842T3 (es) 1993-09-29 1994-09-27 Composicion farmaceutica estabilizada y disolvente estabilizante.

Country Status (28)

Country Link
US (1) US5504102A (es)
EP (1) EP0645145B1 (es)
JP (1) JP3447386B2 (es)
KR (1) KR100515631B1 (es)
CN (1) CN1140297C (es)
AT (1) ATE149843T1 (es)
AU (1) AU686651B2 (es)
BE (1) BE1007987A5 (es)
BR (1) BR1100361A (es)
CA (1) CA2132936C (es)
CY (1) CY2035A (es)
CZ (2) CZ287358B6 (es)
DE (1) DE69402022T2 (es)
DK (1) DK0645145T3 (es)
ES (2) ES2098842T3 (es)
FI (1) FI115825B (es)
GR (1) GR3023583T3 (es)
HK (1) HK96797A (es)
HU (1) HU217962B (es)
IL (1) IL111065A (es)
IT (1) IT1279383B1 (es)
NO (1) NO308447B1 (es)
NZ (1) NZ264526A (es)
PL (1) PL176826B1 (es)
RU (1) RU2107500C1 (es)
SG (1) SG50479A1 (es)
TW (1) TW406020B (es)
ZA (1) ZA947482B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5612694A (en) * 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
AU1214400A (en) * 1998-10-20 2000-05-08 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceuticalcompositions
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
KR20030019327A (ko) * 2000-03-24 2003-03-06 아이박스 리서치 인코포레이티드 탁산-기저 조성물을 안정시키는 금속염의 용도
AU2001253336A1 (en) 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
CA2408548C (en) 2000-05-12 2008-03-11 Samyang Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2001279168A1 (en) * 2000-08-02 2002-02-13 Atossa Healthcare, Inc. Bimodal emulsions of taxanes and butyrate polyalcohol esters
CN1116875C (zh) * 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US6410059B1 (en) * 2000-10-20 2002-06-25 Council Of Scientific And Industrial Research Pharmaceutical composition containing cow urine distillate and an antibiotic
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
EP1355634B8 (en) 2000-11-09 2009-03-04 Neopharm, Inc. Sn-38 lipid complexes and methods of use
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
JP4384409B2 (ja) 2000-12-05 2009-12-16 チルドレンズ・ホスピタル・ロス・アンジエルス バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
WO2002080940A2 (en) 2001-04-06 2002-10-17 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
KR20030023369A (ko) * 2001-09-13 2003-03-19 한국과학기술연구원 화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US6710195B2 (en) * 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
ATE424187T1 (de) * 2002-07-15 2009-03-15 Alcon Inc Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
AU2003291458A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
DE502004009827D1 (de) * 2003-05-19 2009-09-10 Ebewe Pharma Gmbh Nfg Kg Verfahren zur herstellung einer stabilen injizierbaren formulierung von paclitaxel
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
EP1648988A1 (en) * 2003-07-24 2006-04-26 Dabur Research Foundation Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP1947094A3 (en) 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Process for the preparation of taxane derivatives
EP1694242B1 (en) * 2003-12-17 2014-04-16 Bionumerik Pharmaceuticals, Inc. Process for making pharmaceutical 7-(2-trimethylsilylethyl) camptothecin formulations
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CN100548274C (zh) * 2006-01-12 2009-10-14 永信药品工业股份有限公司 紫杉醇水性注射液及其制备方法
US8242165B2 (en) * 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
JP2011509299A (ja) 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
PL2254570T3 (pl) * 2008-02-20 2014-05-30 Actelion Pharmaceuticals Ltd Połączenie zawierające paklitaksel do leczenia raka jajnika
DE102008059201A1 (de) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
PT2769737T (pt) 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
ES2718090T3 (es) * 2010-11-08 2019-06-27 Cadila Pharmaceuticals Ltd Composición farmacéutica de taxoides
EP2884963B1 (en) * 2012-08-15 2017-12-27 Yung Shin Pharm. Ind. Co. Ltd. Stable pharmaceutical formulation of cabazitaxel
AU2014215421A1 (en) * 2013-02-05 2015-08-13 1Globe Health Institute Llc Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
WO2016005962A2 (en) * 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
CN116328361A (zh) * 2023-03-23 2023-06-27 四川汇宇制药股份有限公司 稳定的紫杉醇溶液及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2221157A (en) * 1988-07-21 1990-01-31 Biogal Gyogyszergyar Intravenous pharmaceutical composition comprising cyclosporin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
WO1994012198A1 (en) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Injectable taxol composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830002614B1 (ko) * 1980-04-14 1983-05-30 후로인도 산교오 가부시끼 가이샤 활성화된 의약조성물의 제법
JPS61152621A (ja) * 1984-12-27 1986-07-11 Lion Corp 液状透明口腔用組成物
RO92831B1 (ro) * 1985-07-29 1988-01-01 Viorica Dobrescu Procedeu de purificare a polietilenglicolilor
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
JP2598206B2 (ja) * 1992-07-17 1997-04-09 ツヤック株式会社 蛋白繊維品のハイグラル・エクスパンションの安定化法
AU5612694A (en) * 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2221157A (en) * 1988-07-21 1990-01-31 Biogal Gyogyszergyar Intravenous pharmaceutical composition comprising cyclosporin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
WO1994012198A1 (en) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Injectable taxol composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, Vol. n‘ 14, N‘ 475 (C-770) [4418], 1990 & JP 2196789 A (SANKYO CO. LTD.) *

Also Published As

Publication number Publication date
DE69402022D1 (de) 1997-04-17
DK0645145T3 (da) 1997-04-07
HK96797A (en) 1997-08-08
RU94037231A (ru) 1996-09-27
RU2107500C1 (ru) 1998-03-27
KR100515631B1 (ko) 2005-12-08
CY2035A (en) 1998-02-20
IT1279383B1 (it) 1997-12-10
HUT68687A (en) 1995-07-28
SG50479A1 (en) 1998-07-20
AU686651B2 (en) 1998-02-12
NO308447B1 (no) 2000-09-18
ITRM940621A0 (it) 1994-09-28
EP0645145A2 (en) 1995-03-29
FI115825B (fi) 2005-07-29
JPH07179362A (ja) 1995-07-18
JP3447386B2 (ja) 2003-09-16
NZ264526A (en) 1996-10-28
EP0645145B1 (en) 1997-03-12
CA2132936A1 (en) 1995-03-30
HU9402776D0 (en) 1994-12-28
NO943583L (no) 1995-03-30
IL111065A (en) 2003-03-12
IL111065A0 (en) 1994-12-29
DE69402022T2 (de) 1997-07-17
CZ234994A3 (en) 1995-04-12
HU217962B (hu) 2000-05-28
CZ287485B6 (cs) 2000-12-13
BE1007987A5 (fr) 1995-12-05
ES2098842T3 (es) 1997-05-01
TW406020B (en) 2000-09-21
GR3023583T3 (en) 1997-08-29
BR1100361A (pt) 2000-07-18
CN1140297C (zh) 2004-03-03
ATE149843T1 (de) 1997-03-15
EP0645145A3 (en) 1995-05-24
ZA947482B (en) 1995-05-15
FI944448A0 (fi) 1994-09-26
AU7427394A (en) 1995-04-13
FI944448L (fi) 1995-03-30
PL176826B1 (pl) 1999-07-30
CN1107367A (zh) 1995-08-30
ITRM940621A1 (it) 1996-03-28
US5504102A (en) 1996-04-02
CZ287358B6 (en) 2000-11-15
KR950007872A (ko) 1995-04-15
NO943583D0 (no) 1994-09-27
PL305240A1 (en) 1995-04-03
CA2132936C (en) 1999-06-29

Similar Documents

Publication Publication Date Title
ES2095802A1 (es) Composicion farmaceutica estabilizada y solvente de estabilizacion.
KR890004689A (ko) 니트로글리세린 스프레이
ES2001950A6 (es) Procedimiento de obtencion de composiciones en emulsion para la administracion de farmacos hidrofobos ionizables escasamente hidrosolubles.
ES8800899A1 (es) Procedimiento para preparar derivados de amidoinzol y amidoinzadol
ES549814A0 (es) Un procedimiento para preparar una crema antibacteriana, aplicable por via topica
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
ES2134189T3 (es) Procedimiento para la preparacion de un producto de celulosa oxidado neutralizado y uso del mismo.
UA26375A1 (uk) Спосіб очищеhhя іhсуліhу
ES2051650A1 (es) Procedimiento para preparar un limpiador de oxigeno activo.
ES8401935A1 (es) "procedimiento para la preparacion de beta-lactamas".
ES460743A1 (es) Procedimiento para la obtencion de preparados medicinales con ph acido.
ATE228005T1 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
JPS6416724A (en) Stable and injectable vinca dimer salt solution
KR840006126A (ko) 약학 조성물의 안정화 방법
DE69824326D1 (de) Pharmazeutische Emulsion enthaltend Sorbinsäure, Na-EDTA und Borsäure
ES2086804T3 (es) Procedimiento para la obtencion de carbonatos aromaticos.
JPS6425714A (en) Bathing agent
MX9302924A (es) Agente para tratamiento de cataratas y metodo para su preparacion.
ES2162794T3 (es) Compuestos farmaceuticos que contienen ametocaina.
AR247420A1 (es) Composicion y procedimiento para corregir la productividad y/o capacidad de inyeccion de pozos de petroleo.
ATE30907T1 (de) Verfahren zur stabilisierung von chlorkohlenwasserstoffen, verfahrensgemaess stabilisierte chlorkohlenwasserstoff und ihre verwendung.
KR960705565A (ko) 테르페나딘과 이부프로펜의 안정한 약제학적 조성물(A stable pharmaceuitical composition of terfenadine and ibuprofen)
ATE461711T1 (de) Zusammensetzung zur stabilisierung von fettlöslichen vitaminen in wässeriger lösung
TW252042B (en) Injectable pharmaceutical composition containing piroxicam potassium
JPS5271414A (en) Storage of aqueous cationic monomer solution

Legal Events

Date Code Title Description
FB1A Application suspended

Effective date: 19960617

EC2A Search report published

Date of ref document: 19970216

Kind code of ref document: A1

Effective date: 19970216

FA2A Application withdrawn

Effective date: 19970415